Developing new treatments for glioblastoma that resist a common drug
Perivascular tissue models to overcome MGMT-mediated temozolomide resistance in glioblastoma
['FUNDING_R01'] · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · NIH-11212142
This study is looking at glioblastoma, a tough type of brain cancer, to find better ways to treat it by creating models that mimic the tumor environment, which could help develop new drugs that work even when the cancer becomes resistant to standard treatments.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN (nih funded) |
| Locations | 1 site (CHAMPAIGN, UNITED STATES) |
| Trial ID | NIH-11212142 on ClinicalTrials.gov |
What this research studies
This research focuses on glioblastoma, a highly aggressive brain cancer that often becomes resistant to the standard treatment drug temozolomide (TMZ). The team aims to create advanced tissue models that mimic the tumor environment, allowing for better understanding of how glioblastoma invades surrounding tissues and how it resists treatment. By using innovative materials and techniques, they will explore new drug derivatives that could effectively target glioblastoma cells, even those that express the resistance protein MGMT. Patients may benefit from more effective treatment options that could improve survival rates and quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma, particularly those who have shown resistance to temozolomide.
Not a fit: Patients with other types of brain tumors or those who do not have glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for glioblastoma patients who currently have limited treatment options.
How similar studies have performed: Other research has shown promise in developing novel therapies for glioblastoma, but this approach using engineered tissue models and new drug derivatives is relatively novel.
Where this research is happening
CHAMPAIGN, UNITED STATES
- UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN — CHAMPAIGN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HARLEY, BRENDAN A. — UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN
- Study coordinator: HARLEY, BRENDAN A.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer